ValuEngine lowered shares of Acceleron Pharma Inc. (NASDAQ:XLRN) from a hold rating to a sell rating in a research note published on Friday, October 6th.
Several other research firms have also recently weighed in on XLRN. Credit Suisse Group set a $35.00 target price on shares of Acceleron Pharma and gave the company a buy rating in a research note on Saturday, August 5th. Oppenheimer Holdings, Inc. reiterated a market perform rating on shares of Acceleron Pharma in a research note on Tuesday, June 13th. Piper Jaffray Companies increased their target price on shares of Acceleron Pharma from $32.00 to $40.00 and gave the company an overweight rating in a research note on Monday, June 26th. Cann reiterated a hold rating on shares of Acceleron Pharma in a research note on Tuesday, September 5th. Finally, BidaskClub cut shares of Acceleron Pharma from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Acceleron Pharma has a consensus rating of Buy and a consensus price target of $43.65.
Shares of Acceleron Pharma (XLRN) opened at 38.01 on Friday. Acceleron Pharma has a 52 week low of $23.07 and a 52 week high of $41.69. The firm’s 50-day moving average price is $37.79 and its 200 day moving average price is $32.25. The firm’s market cap is $1.47 billion.
Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.12). Acceleron Pharma had a negative net margin of 724.22% and a negative return on equity of 44.67%. The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.69 million. During the same period in the prior year, the business posted ($0.59) earnings per share. The company’s revenue for the quarter was down 3.1% compared to the same quarter last year. Equities analysts anticipate that Acceleron Pharma will post ($2.69) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Acceleron Pharma Inc. (NASDAQ:XLRN) Rating Lowered to Sell at ValuEngine” was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://baseballnewssource.com/markets/acceleron-pharma-inc-xlrn-stock-rating-lowered-by-valuengine/1697787.html.
In other news, SVP Ravindra Kumar sold 13,065 shares of Acceleron Pharma stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $35.41, for a total value of $462,631.65. Following the completion of the transaction, the senior vice president now owns 108,392 shares in the company, valued at $3,838,160.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP John D. Quisel sold 5,113 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total transaction of $196,441.46. Following the completion of the transaction, the senior vice president now owns 57,918 shares of the company’s stock, valued at approximately $2,225,209.56. The disclosure for this sale can be found here. Insiders sold 66,578 shares of company stock valued at $2,518,117 in the last quarter. 3.90% of the stock is currently owned by corporate insiders.
Several large investors have recently bought and sold shares of XLRN. Nationwide Fund Advisors raised its stake in shares of Acceleron Pharma by 10.5% in the first quarter. Nationwide Fund Advisors now owns 22,737 shares of the biopharmaceutical company’s stock valued at $602,000 after acquiring an additional 2,168 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of Acceleron Pharma by 88.9% in the first quarter. Russell Investments Group Ltd. now owns 27,850 shares of the biopharmaceutical company’s stock valued at $737,000 after acquiring an additional 13,108 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Acceleron Pharma by 106.1% in the first quarter. Wells Fargo & Company MN now owns 79,462 shares of the biopharmaceutical company’s stock valued at $2,104,000 after acquiring an additional 40,910 shares during the last quarter. Parametric Portfolio Associates LLC bought a new position in shares of Acceleron Pharma in the first quarter valued at approximately $241,000. Finally, American International Group Inc. raised its stake in shares of Acceleron Pharma by 7.1% in the first quarter. American International Group Inc. now owns 16,878 shares of the biopharmaceutical company’s stock valued at $447,000 after acquiring an additional 1,119 shares during the last quarter. Institutional investors own 77.35% of the company’s stock.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with our FREE daily email newsletter.